In general, PARPi performed better when used in combination with other drugs than when used alone for the treatment of a wide variety of haematological malignancies, with only two studies reporting an antagonistic effect whereby olaparib blocked cisplatin-induced cell death in CML and IDH1/2 mutation inhibitors blocked olaparib and talazoparib in AML cell lines. This evidence concerns the gene IDH1 and chronic myelogenous leukemia, BCR-ABL1 positive.